BofA Remains Bullish on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 14, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) and set a price target of $6.00.

The rating update came after the company announced on May 12 plans to present at the BofA Securities 2025 Healthcare Conference.

A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment.

In addition, Sana Biotechnology, Inc. (NASDAQ:SANA) presented positive 4- and 12-week clinical results for its ongoing type 1 diabetes study. The company plans to file Investigational New Drug applications (INDs) for SG299 in B-cell-related diseases and for SC451 in type 1 diabetes as early as 2026.

As of fiscal Q1 2025, Sana Biotechnology, Inc. (NASDAQ:SANA) has a cash position of $104.7 million, with an expected cash runway into 2026.

Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineering cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders.

While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.